1
George V Guittard, Joseph C Deters, Felix Theeuwes, Richard Cortese: Osmotic system with instant drug availability. ALZA Corporation, Paul L Sabatine, Edward L Mandell, Steven F Stone, March 18, 1986: US04576604 (106 worldwide citation)

An osmotic device is disclosed for delivering a beneficial agent. The device comprises a wall surrounding a compartment containing an agent, a passageway in the wall connecting the exterior of the device with the compartment, and (a) an agent in the wall or (b) an agent carried on the wall in the wa ...


2
Jerry D Childers, George V Guittard, Glen E Barclay, Anthony L Kuczynski, Patrick S L Wong: Hydrocodone therapy. ALZA Corporation, Paul Sabatine, Susan K Thomas, Michael J Rafa, February 2, 1999: US05866161 (84 worldwide citation)

A hydrocodone composition, a hydrocodone dosage form, and a method of administering hydrocodone are disclosed and indicated for hydrocodone therapy.


3
Patrick S L Wong, Felix Theeuwes, George V Guittard, Atul D Ayer: Method of therapy comprising an osmotic caplet. Alza Corporation, Paul L Sabatine, Susan K Thomas, Michael J Rafa, February 9, 1999: US05869097 (79 worldwide citation)

An osmotic caplet is disclosed comprising an osmotic caplet exit for delivering a preselected dose of drug to a patient in need of therapy.


4
George V Guittard, Joseph C Deters, Felix Theeuwes, Richard Cortese: Osmotic system with instant drug availability. Alza Corporation, Paul L Sabatine, Edward L Mandell, Steven F Stone, June 16, 1987: US04673405 (72 worldwide citation)

An osmotic device is disclosed for delivering a beneficial agent. The device comprises a wall surrounding a compartment containing drug, a passageway in the wall connecting the exterior of the device with the compartment, and drug in the wall. The device delivers the drug from the compartment and th ...


5
Jerry D Childers, George V Guittard, Glen E Barclay, Anthony L Kuczynski, Patrick S L Wong: Hydrocodone therapy. ALZA Corporation, Robert R Neller, December 10, 2002: US06491945 (58 worldwide citation)

A hydrocodone composition, a hydrocodone dosage form, and a method of administering hydrocodone are disclosed and indicated for hydrocodone therapy.


6
George V Guittard, Francisco Jao, Susan M Marks, David J Kidney, Fernando Gumucio: Dosage form comprising oxybutynin. ALZA Corporation, Paul L Sabatine, Steven F Stone, Michael J Rafa, November 24, 1998: US05840754 (53 worldwide citation)

A composition comprising oxybutynin, a device comprising oxybutynin, and a method for administering oxybutynin are disclosed for oxybutynin therapy.


7
George V Guittard, Howard A Carpenter, Ernest S Quan, Patrick S Wong, Lawrence G Hamel: Dosage form for delivering drug in short-time period. Alza Corporation, Paul L Sabatine, Jacqueline S Larson, Jean M Duvall, January 12, 1993: US05178867 (43 worldwide citation)

The invention pertains to a dosage form for orally administering a drug in eight hours or less to the stomach and small intestine for a therapeutic result.


8
Larry G Hamel, Felix A Landrau, George V Guittard, Patrick S L Wong: Pseudoephedrine dosage form. ALZA Corporation, Paul L Sabatine, Edward L Mandell, Steven F Stone, January 31, 1989: US04801461 (43 worldwide citation)

A dosage form is disclosed for delivering the beneficial drug pseudoephedrine to a biological environment of use.


9
Jeremy C Wright, George V Guittard: Dosage form for delivering drug to the intestine. ALZA Corporation, Paul L Sabatine, Jacqueline S Larson, Jean M Duvall, January 12, 1993: US05178866 (43 worldwide citation)

A drug delivery device is disclosed for delivering a drug to the intestine and the colon. The device comprises external means for delaying the delivery of drug in the stomach, and hydrophobic means for preventing the passage of fluid through the delay means.


10
George V Guittard, Francisco Jao, Susan M Marks, David J Kidney, Fernando E Gumucio: Alza Corporation, Paul L Sabatine, Michael J Rafa, Susan K Thomas, June 15, 1999: US05912268 (36 worldwide citation)

A composition comprising oxybutynin, a device comprising oxybutynin, and a method for administering oxybutynin are disclosed for oxybutynin therapy.